PARP1 and central nervous system cancer: The effects of PARP inhibition on TMZ sensitivity have also been tested in glioma models, including conventional and primary cell lines and xenografts [19–25], BTICs and xenografts [19, 21, 23], and syngeneic and genetically modified animal models [16, 26].